Non-Invasive Prenatal Test Assessment of Trisomy 21 (Down Syndrome): Large Scale Validity Study.

Objective of this study was to validate the clinical efficacy and practical feasibility of massively parallel maternal plasma DNA sequencing to screen for fetal trisomy 21 among high risk pregnancies clinically indicated for amniocentesis or chorionic villus sampling. Diagnostic accuracy validated against full karyotyping, using prospectively collected or archived maternal plasma samples. Participants: 753 pregnant women at high risk for fetal trisomy 21 who underwent definitive diagnosis by full karyotyping, of whom 86 had a fetus with trisomy 21.

Results were available from 753 pregnancies with the 8-plex sequencing protocol and from 314 pregnancies with the 2-plex protocol. The performance of the 2-plex protocol was superior to that of the 8-plex protocol. With the 2-plex protocol, trisomy 21 fetuses were detected at 100% sensitivity and 97.9% specificity, which resulted in a positive predictive value of 96.6% and negative predictive value of 100%. The 8-plex protocol detected 79.1% of the trisomy 21 fetuses and 98.9% specificity, giving a positive predictive value of 91.9% and negative predictive value of 96.9%.

Conclusion: Multiplexed maternal plasma DNA sequencing analysis could be used to rule out fetal trisomy 21 among high risk pregnancies. If referrals for amniocentesis or chorionic villus sampling were based on the sequencing test results, about 98% of the invasive diagnostic procedures could be avoided.

 BMJ 2011; 342:c7401  (Published 11 January 2011)


Quick Contact

Fill out the form below and one of our executives will get in touch with you.

Prenatal paternity and gender DNA test Montreal Toronto Winnipeg Calgary Edmonton Vancouver London


Benefits of Doing Non-invasive Prenatal Paternity Testing with Our Laboratory

       Our laboratory is offering a full package for our clients: a.     Free pretesting consultation for your case: explanation about prenatal …

Read More

Our clients online